Companies / France
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
GSK Invests In Massive Vaccines Plant
October 2006 | FDI AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Demonstrating confidence in France's business environment, UK drugmaker GlaxoSmithKline (GSK) is to invest EUR500mn (US$637mn) in a new vaccine production plant in St Amand-Les-Eaux, France, near the Belgian border. It is BMI's view that the move was designed to meet booming demand for GSK's adult and paediatric vaccines, and anticipated strong uptake of Cervarix, a revolutionary cervical cancer vaccine that is expected to enter the market next year.